Teva Pharmaceutical Industries Gross Profit 2010-2024 | TEVA

Teva Pharmaceutical Industries annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Teva Pharmaceutical Industries gross profit for the quarter ending June 30, 2024 was $2.024B, a 12.69% increase year-over-year.
  • Teva Pharmaceutical Industries gross profit for the twelve months ending June 30, 2024 was $8.063B, a 18.28% increase year-over-year.
  • Teva Pharmaceutical Industries annual gross profit for 2023 was $7.646B, a 9.65% increase from 2022.
  • Teva Pharmaceutical Industries annual gross profit for 2022 was $6.973B, a 8.18% decline from 2021.
  • Teva Pharmaceutical Industries annual gross profit for 2021 was $7.594B, a 1.71% decline from 2020.
Teva Pharmaceutical Industries Annual Gross Profit
(Millions of US $)
2023 $7,646
2022 $6,973
2021 $7,594
2020 $7,726
2019 $7,536
2018 $8,296
2017 $10,615
2016 $11,859
2015 $11,356
2014 $11,056
2013 $10,707
2012 $10,652
2011 $9,515
2010 $9,065
2009 $7,367
Teva Pharmaceutical Industries Quarterly Gross Profit
(Millions of US $)
2024-06-30 $2,024
2024-03-31 $1,771
2023-12-31 $2,417
2023-09-30 $1,851
2023-06-30 $1,796
2023-03-31 $1,582
2022-12-31 $1,770
2022-09-30 $1,669
2022-06-30 $1,794
2022-03-31 $1,740
2021-12-31 $2,049
2021-09-30 $1,794
2021-06-30 $1,873
2021-03-31 $1,878
2020-12-31 $2,048
2020-09-30 $1,852
2020-06-30 $1,763
2020-03-31 $2,063
2019-12-31 $1,958
2019-09-30 $1,829
2019-06-30 $1,893
2019-03-31 $1,856
2018-12-31 $1,971
2018-09-30 $1,977
2018-06-30 $2,033
2018-03-31 $2,315
2017-12-31 $2,271
2017-09-30 $2,650
2017-06-30 $2,855
2017-03-31 $2,839
2016-12-31 $3,390
2016-09-30 $2,801
2016-06-30 $2,877
2016-03-31 $2,791
2015-12-31 $2,847
2015-09-30 $2,771
2015-06-30 $2,902
2015-03-31 $2,836
2014-12-31 $2,889
2014-09-30 $2,809
2014-06-30 $2,661
2014-03-31 $2,697
2013-12-31 $2,894
2013-09-30 $2,630
2013-06-30 $2,593
2013-03-31 $2,590
2012-12-31 $2,785
2012-09-30 $2,601
2012-06-30 $2,657
2012-03-31 $2,609
2011-12-31 $2,881
2011-09-30 $2,246
2011-06-30 $2,200
2011-03-31 $2,188
2010-12-31 $2,464
2010-09-30 $2,467
2010-06-30 $2,121
2010-03-31 $2,013
2009-12-31 $2,099
2009-09-30 $1,928
2009-06-30 $1,769
2009-03-31 $1,571
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $20.902B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00